BCL2L11 and melanoma: Loss of PTEN, which is observed in 10-33% of melanoma specimens [14-16], may contribute to intrinsic resistance to BRAFi via increased PI3K/AKT signaling when BRAF is inhibited and suppression of apoptosis mediated by proapoptotic protein BIM, member of the Bcl-2 protein family [14].